VTV THERAPEUTICS INC- CL A (VTVT)

Company Profile

vTv Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in High Point, North Carolina and currently employs 13 full-time employees. The company went IPO on 2015-07-30. vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes HPP593, Nrf2/Bach1 Modulator Program, Azeliragon and HPP3033.

Company Info

VTV THERAPEUTICS INC- CL A

3980 Premier Dr, Suite 310

High Point NORTH CAROLINA 27265

P: 13368410300

CEO: Stephen L. Holcombe

Employees: 13

Website: https://vtvtherapeutics.com/